LRH-1 modulators (University of California San Francisco)

N/A

Report date: 2025/01/15 13:54:29
NME

Base Information

Drug NameLRH-1 modulators (University of California San Francisco)
Drug Alias NameLRH-1 modulators (inflammatory bowel disease/type-2 diabetes/cancer), University of California San Franciscoliver receptor homolog-1 modulators (University of California San Francisco)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor subfamily 5 group A member 2 modulators
TargetsNuclear receptor subfamily 5 group A member 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Inflammatory Bowel DiseasesTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoUniversity Of California
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Inflammatory Bowel DiseasesTriple Negative Breast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A